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ABSTRACT 
Background: Life-saving highly active anti-retroviral therapy (HAART) has been 
accompanied by the challenge of incident adverse drug reactions (ADRs). Locally 
generated data is scanty, inadequately documented, and therefore not available to 
inform revision of clinical protocols. 
Objective: To study and document the magnitude and type of ADRs associated with 
HAART over a 42 month period at Mbagathi District Hospital (MDH) Nairobi. 
Design: A retrospective cohort study. 
Setting: A high burdened HIV comprehensive care clinic based at the Mbagathi District 
Hospital in Nairobi, Kenya. 
Subjects: HIV infected patients receiving highly active anti-retroviral therapy 
(HAART) 
Results: Adverse drug reactions associated with HAART occurred in 63% of adult 
study subjects. Majority (91.4%) of the ADRs experienced were medium to long term 
conditions, namely peripheral neuropathy in 33.3%, lipodystrophy in 32.6%, hepatic 
toxicity in 24.4% and lactic acidemia in 4.1 % of patients. Furthermore, occurrence of all 
the ADRs was associated with increasing baseline age (p<0.0001). Gender differences 
were found in patients with lipodystrophy (p<0.001), and lactic acidemia (p=0.047), 
with a female preponderance. 
Conclusion: Adverse drug reactions were experienced by 63% patients on HAART. 
Majority of the ADRs were those commonly associated with the medium to long 
term use of stavudine and nevirapine. Despite the high frequency of ADRs, patient 
outcomes were favourable as there were no reported deaths or hospitalisations. 
INTRODUCTION 
The past decade has seen the introduction of highly 
active anti-retroviral therapy (HAAR T) which has 
dramatically reduced morbidity and mortality from 
HIV - related complications and improved the quality 
of life among HIV infected patients worldwide (1). 
However, HAART has been associated with incident 
of adverse drug reactions (ADRs) (2). Adverse events 
are the key underlying factors to therapy change 
or non-adherence to medicines (3, 4). Patients with 
ADRs are nearly 13 times less likely to have 95-100% 
adherence and likely to experience three and a half 
times increased risk of virologic, immunologic and 
clinical failure. (5). 
 The occurrence and magnitude of ADRs in 
developed countries is well documented, while 
this is not the case in developing countries. In this 
regard, locally generated data are required to improve 
clinical protocols and outcomes in Kenya. This study 
examined ADRs associated with HAART in adult 
study subjects and their possible risk factors over a 
42 month period in a high burdened public health 
facility, the Mbagathi District Hospital, Nairobi. 
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MATERIALS AND METHODS
This was a retrospective cohort study design. It 
examined the clinical encounters of patients managed 
at the MDH over a three and a half year period (from 
mid 2003 to the end of 2007). By December 2007, over 
7,374 patients had registered to receive comprehensive 
HIV care and out of this number, 4,034 patients 
were on HAART. The HAART regimens used at the 
hospital complied with the Kenya National HAART 
Guidelines (6) that predominately utilise stavudine 
based regimens. 
 Stratified random sampling proportional to size 
of the adult HAAR T population was used to select 
the study subjects. Data on bio-demographic, clinical 
and immunologic parameters, treatment regimens, 
duration of treatment to experiencing ADRs, types 
of ADRs experienced and the outcome of the ADRs 
were extracted from the study subjects’ medical 
records. These data were analysed using Statistical 
Package for Social Sciences (SPSS) TM version 12.0 
for Windows. Descriptive statistics, Chi-square test of 
statistic, bivariate comparisons of baseline continuous 
symmetric characteristics, linear mixed-effect models 
were used to characterise the experienced ADRs, 
establish change in continuous variables (such as CD4 
counts, weight and age), and determine statistical 
associations and levels of significance. The analyses 
characterised the number and type of adverse 
reactions, computed odds ratios, and determined risk 
for occurrence of the ADRs and possible significant 
risk factors associated with ART. 
 Ethical clearance was granted by the committees 
of Kenyatta National Hospital and College of Health 
Sciences, University of Nairobi and the Ministry of 
Science and Technology. 
RESULTS 
A total of 414 adult study subjects were sampled 
from 4,034 patients on HAART. These study subjects 
had a mean baseline age and weight of 34.1 years 
(standard deviation (sd)±7.84) and 57.9 Kg (sd 
±10.6) respectively. Using random sampling with 
stratification by gender, the study subjects comprised 
65.9% (272/413) female patients and 34.1 % (141/413) 
males. About 68.6% (179/261) of patients with 
ADRs were females, while 31.4% (82/261) were 
males patients. Despite this finding gender was not 
a significant risk factor in the occurrence of ADR, 
p=0.127 (Table 1). 
 Sixty percent (154/259) of patients with ADRs 
had been commenced on D4T30/3TC/NVP (Table 
1). The second highest (n= 69, 26.6%) number of 
patients with ADRs were patients on D4T40/3TC/
NVP. Seventy seven percent (1191154) of patients with 
ADRs and commenced on D4T30/3TC/NVP were 
female while 22.73% (351154) were males. Among 
patients with ADRs started on D4T40/3TC/NVP, 
60.87% (42/69) were females and 39.13% (27/69) 
were males. Similarly, the one female patient started 
on AZT based regimen also experienced an ADR. 
 Eighty six percent (223/259) of patients with 
ADRs had been commenced on NVP based regimens 
while 13.9 % (36/259) were on EFV based regimens 
(Table 1). Among the females with ADRs, 91.2% 
(1651181) were on NVP based regimens, while 8.8% 
(161181) were on EFV based regimens. Among the 
males with ADRs, 75.61 % (62/82) of patients were 
on NVP based regimens while 24.39% (20/82) were 
on EFV based regimens. 
Table 1
Comparison of Existence of ADRs with Patient Bio-Demographic and Immunological Factors 
    Patients who had ADRs  P –values
  Total no. % No no. (%)  Yes no. (%) 
Gender N=413 
 - Male 141(34.14) 59(38.82) 82(31.42) Referent 
 - Female  272(65.86) 93(61.18) 179(68.58) 0.127
Marital status N=410 
 - Married  189(46.10) 72(47.37) 117(45.35) Referent
 - Single 110(26.83) 41(26.97)  69(26.74) 0.888
 - Widowed 69(16.83)  20(13.16) 49(19.0) 0.178
 - Divorced  42(10.24) 19(12.50) 23(8.91) 0.392
WHO stage N=412 
 Stage 1 and 2  39(9.47) 13(8.55) 26(10.00) Referent
 Stage 3 325(78.88)  123(80.92) 202(77.69) 0.582
 Stage 4 48(11.65)  16(10.53) 32(12.31) 0.999
ART regimen at baseline 
N=410 
 D4 T30/3 TC/NVP 240(58.25) 86(56.21) 154(59.46) Referent
 D4 T30/3 TC/EFV 43(10.44) 15(9.80) 28(10.81) 0.905
 D4 T 40/3 TC/NVP  116(28.16) 47(30.72) 69(26.64) 0.392
 D4 T40/3 TC/EFV  13(3.16) 5(3.27) 8(3.09) 0.894
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Types of Adverse Drug Reactions: Sixty three percent 
(95% CI 58.4-67.7%), of patients experienced one or 
more ADRs during the study period (Table 2). Exactly, 
64.4% (168/261) of study subjects who manifested a 
reaction had one ADR, 26.5% (69/261) had two, while 
9.3% (24/261) had three different types of ADRs within 
the study period. 
 When all the ADRs were considered collectively, 
binary logistic regression model revealed significant 
correlation between occurrence and increasing baseline 
age (p<0.0001) but not with baseline CD4 cell counts 
(p=0.944). For every additional year at baseline, the 
probability of experiencing an ADR increased by 7.6 
% (OR 1.076, 95% CI 1.044- 1.108, p< 0.0001). 
 Hepatic toxicity, lipodystrophy, lactic acidosis 
and peripheral neuropathy were the key medium to 
long term adverse reactions experienced by patients 
in the study period. They collectively comprised 
91.4% (391/428) of all the incidents of ADRs and 
had an incidence rate of 49% per 100 person years. 
About 33% of patients (n=138, 95% CI 28.8-37.9%) 
had peripheral neuropathy, while lipodystrophy 
occurred in 32.6% (n=135, 95% CI 28.07- 37.14%) and 
hepatic toxicity in 24.4% (n=l 01, 95% CI 20.4-28.55%) 
and lactic acidemia in 4.1 % (n=17, 95% CI 2.19, 6.03) 
of patients. Approximately, 13% (42/335) of patients 
experienced severe forms of these ADRs. 
 Lipodystrophy and lactic acidemia were the 
only two adverse reactions where the female patients 
were significantly more affected than their male 
counterparts (p<0.001 and p=0.047 respectively). 
Seventy nine percent (1071135) of female patients 
experienced lipodystrophy compared to 20.7% 
(28/135) of male patients. Exactly, 88.2% (15117) of 
female patients and 11.8 % (2117) of male patients 
experienced lactic acidemia (Table 2).
Table 2
Types of ADRs in Adult HAART Patients by Gender (n=261) 
Occurrence of         Mean baseline CD4    Female n    Male    p-   
ADRs    n (%)    95% CI  cell count (95%CI)    (%)    N(%)   value   
   or (sd)         
Overall    261    58.37-       179    82     
         131.5(120.1,141.9)          0.127   
   (63.04) 67.71     (68.58)    (31.42)     
Anemia    3(0.72)  207.00(sd±128.57)    2(66.67)    1(33.33)     
CNS symptoms    3(0.72)      122.00(sd±148.35)    1(33.33)    2(66.67)     
GIT symptoms    7(1.69)      97.83(22.02,173.6)    5(71.43)    2(28.57)     
Hepatic    101    20.24,           
         120.4(103.2,137.6)    65(64.36)    36(35.64) 0.749   
toxicity    (24.40) 28.55     
   135    28.07,        107       
Lipodystrophy         130.2(115.5,145.0)      (79.26) 28(20.74)   <0.001   
   (32.61) 37.14   
Muscle pain    7(1.69)      109.71(40.7,178.7)    4(57.14)    3(42.86)    0.25   
Peripheral    138    28.77,           
         125.3(110.4,140.3)    90(65.22) 48(34.78) 0.785   
neuropathy    (33.33) 37.89     
Skin Reactions 15(3.62)   1.82, 5.43 172.3(122.8,221.8)    7(46.67)    8(55.33)    0.904   
Lactic acidemia  17(4.11)   2.19,6.03    117.88(77.2,158.6)    15(88.24)    2(11.76) 0.047   
Others    2(0.48)      138.00(sd±45.25)    0(0) 2(100.0)
Factors associated with the medium to long term ADRs: 
When the data were adjusted for ARV regimens, 
bio-demographic factors, immunologic status and 
ADRs, there were no significant associations found 
between the occurrence of these ADRs with baseline 
weight, age and gender. Irrespective of the baseline 
regimen, data analysis showed slightly increased risk 
of experiencing the ADRs associated with increasing 
baseline CD4 cell count, HR 1.002 (95% CI 1.00-1.003, 
p=0.011). 
 After adjusting for bio-demographic factors, 
immunological and NRTI based regimens, single 
unmarried patients had a reduced risk of experiencing 
these ADRs (Hazard Ratio (HR) 0.66, 95% CI 0.45-
0.97) compared to divorced patients, p=0.035. When 
the risk for these ADRs was assessed in patients on 
D4T and AZT as compared to other NRTIs, namely 
TDF and ABC, patients on D4T had a higher risk by 
4.4 times (HR 4.42,95% CI 3.04-6.42, p<0.0001). On 
other hand, those on AZT based regimens had a 2.1 
times higher risk of experiencing one of these ADRs 
(HR 2.11,95% CI 1.36-3.3; p<0.0001). 
The risk of having any of these ADRs was also explored 
among patients on EFV, NVP and Lopinavirlritonavir 
(LPV/r) based regimens. The risk of developing these 
ADRs in patients on EFV based regimens compared 
to those on LPV/r was less by 86% (HR 0.14, 95% CI, 
0.0530.37; p<0.0001), while the risk of ADR in among 
those using NVP based regimens was less by 46.6% 
compared with those on LPV/r (HR 0.53,95% CI 
0.37-0.78; p=0.001). 
DISCUSSION 
The HIV infection is one of the specific factors that 
increase the risk of general adverse drug reactions 
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(7). Among the MDH adult HIV study subjects, 63% 
HIV positive study subjects on HAART experienced 
ADRs. Nearly (90%) all the HAART patients were 
commenced on D4T based regimens as per the 
national treatment guidelines that were in effect at 
the time of the study period. 
Types of adverse drug reactions: A few of the more 
persistent or severe short term ADRs were recorded. 
The type of short term ADRS and the proportion 
of the affected areas of the body were as follows: 
central nervous system symptoms (0.7%), skin 
hypersensitivity rashes (3.6%), myopathy (1.5%), GIT 
symptoms (1.5%). As in other similar studies where 
D4T based regimens are predominantly used, the most 
common ADRs recorded were peripheral neuropathy 
(33%), lipodystrophy (33%), hepatic toxicity (24.4%) 
and lactic acidemia (4.1 %) (8-11). These are known 
toxicities of NR TIs over the medium to long-term and 
thought to be secondary to inhibition of mitochondrial 
DNA polymerase b (9). The four ADRs comprised 
91.4% of all the incident ADR reactions and had an 
incidence rate of 49% per 100 person years. 
Factors associated with medium to long term ADRs: 
Increasing age was the only bio-demographic factor 
found to be associated with occurrence of ADRs. For 
every additional year at baseline, the probability of 
experiencing medium to long term ADR increased 
7.6%. This is consistent with literature and is possibly 
due to age-related alteration in pharmacokinetics 
and pharmacodynamics (12). Occurrence of ADRs 
was independent of gender, marital status, baseline 
CD4 cell count. 
 The female gender was not a significant risk 
factor to occurrence of ADRs collectively (p=0.127). 
This finding concurred with studies conducted 
by Johnson et al (13). More specifically, Menezes 
de Padua et al showed that there is a two-fold 
heightened ADR risk among the female gender to 
short term reactions that occurred before the fourth 
month of HAART, such as GI symptoms and allergy 
(14). This study demonstrated that occurrence 
of lipodystrophy (p<0.001) and lactic acidemia 
(p=0.047) were associated with the female gender. 
Similarly, Bonfanti et al demonstrated increased risk of 
lipodystrophy among the females (15). Furthermore, 
the higher risk of lactic acidosis in the female gender 
was demonstrated by Bonnet et al, Geddes et al and 
Boulassel et al (16-18). The increased propensity for NR 
TI -related adverse events in women may be related to 
higher levels of intercellular phosphorylation (19). 
 This study demonstrates that adult HIV positive 
patients on D4T and AZT based regimens had 
increased risk of experiencing ADRs compared to 
their counterparts on TDF or ABC based regimens 
by four and two times respectively. TDF is a much 
safer medicine than either D4T or AZT (20). This 
has been replicated in several settings and has led to 
recent guideline changes for HAART management 
internationally (20). 
 The risk of ADRs in adult HIV positive patients 
on EFV based regimens was less by 86% compared 
to patients on LPV/r based regimens (HR 0.14,95% 
CI, 0.053-0.37; p<0.0001). While the risk of ADR in 
those using NVP based regimens was less by 46.6% 
than for those on LPV/r (HR 0.53,95% CI 0.37-0.78; 
p=0.001). Based on these results, it appears as if EFV 
and NVP are safer than LPV/r. However, the patients 
on LPV/r were more likely to have been on HAART 
for longer and most probably were switched from 
NVP or EFV at one point in time. Additional study 
with adjustments for length of time on the individual 
ARVs may be needed to determine the true correlation 
between these medicines and risk of ADRs. 
 Despite the high frequency of ADRs among 
patients on HAART, the outcomes were favourable 
as there were no documented incidences of deaths or 
hospitalisations. In addition, a proportion of patients 
(44-59%) with medium to long term ADRs already 
had resolution of their reactions by end of the study 
period. 
Limitations: First, this was a retrospective cohort 
study using routinely collected clinical data without 
independent real time confirmation of existence of 
adverse events or their outcome. However, this was 
minimised with the use of standardised patient clinical 
encounter forms based on the national protocols, 
designed to systematically collect information 
from clinical encounters. Non naive patients were 
also excluded from the study, because of increased 
likelihood of non availability of initial data. 
 Second, the ADRs documented in patient records 
were based on the clinical acumen of the clinicians, 
without independent laboratory and radiological 
confirmation of the existence of the event in the 
majority of cases. Variability was minimised by the use 
of standardised validated protocols. Lipodystrophy 
was the only ADR that would need additional case 
definition and validation to describe severity of the 
event. This has not yet been done by the world medical 
fraternity. 
 Third, it was not possible to study other factors, 
for lack of sufficient data, that could influence the 
occurrence of ADRs such as viral hepatitis, renal 
insufficiency, and alcohol consumption. 
 Despite these limitations and considering that 
this was a baseline study among the MDH HAART 
cohort, it is we believed that the findings are suitable 
and valid for informing programme and clinical 
management and comparing with other national, 
regional and global HAAR T cohorts studies. 
In conclusion the ADRs that occurred frequently 
among HAART patients and were largely associated 
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with the medium to long term use of stavudine and 
nevirapine. Over a follow-up period of three and a half 
years approximately 63% of HIV infected patients on 
HAART presented with an ADR. Patients on D4T and 
AZT were significantly at higher risk of experiencing 
ADRs than their counterparts on TDF and ABC. In 
addition, increasing age at initiation of therapy was 
found to be the only bio-demographic risk factor. 
Despite the high frequency of ADRs there were no 
reported deaths or hospitalisations.
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